Stockreport

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma [Yahoo! Finance]

Genmab A/S - American Depositary Shares  (GMAB) 
PDF refractory (R/R) follicular lymphoma (FL) who had received two or more lines of systemic therapy EPKINLY is the first and only T-cell engaging bispecific antibody admi [Read more]